Defining skin cancer local recurrence.

Definitions of skin cancer recurrence are variable and nonstandardized, which can lead to inconsistent and potentially inappropriate management of tumors of uncertain recurrence status. Defining recurrence is important given the potential association with metastasis in both melanoma and nonmelanoma skin cancer. A review of the literature across multiple disciplines involved in the care of skin cancer patients reveals that although criteria for recurrence are provided in the majority of cases, most are vague and inconsistent. Given the presumably increased morbidity and mortality associated with recurrent tumors, accurate identification and appropriate management is paramount. In addition, value-based health care necessitates validated and relevant outcome measures that are standardized and, thus, enable tracking of comparable and corresponding outcomes. A universal definition of localized skin cancer recurrence would ultimately allow for improved surveillance and informed therapeutic strategies to decrease morbidity and mortality of patients afflicted with skin cancer, the most common cancer nationwide.

Safety of peak serum lidocaine concentration after Mohs micrographic surgery: a prospective cohort study.

BACKGROUND: Large volumes of dilute local anesthesia are increasingly used not only for liposuction but also for other large cutaneous surgeries, including skin cancer excision. Although the lidocaine serum levels and peaks after injection of tumescent anesthesia in the trunk were shown to be safe even when used in high doses, the levels after use of less dilute (1% lidocaine) solutions for facial cancer surgery have not been described. OBJECTIVE: We sought to ascertain whether perioperative peak lidocaine levels during Mohs micrographic surgery approach thresholds for lidocaine toxicity. METHODS: In this prospective cohort study, each Mohs micrographic procedure was commenced per routine protocol, with use of injectable 1% lidocaine with 1:200,000 epinephrine and 1:10 8.4% bicarbonate for local anesthesia. Six peripheral blood draws of 5 mL each were performed and sent for serum lidocaine concentration measurement. Blood draws were obtained before and after the first two stages of Mohs micrographic surgery, and before and after the third stage or wound repair, as appropriate. Subjects and investigators reported any symptoms or signs of lidocaine toxicity. The main outcome measures include: (1) number of subjects exhibiting at least one level higher than the threshold for toxicity; and (2) sustained elevated lidocaine levels in one or more subjects. RESULTS: Mean total lidocaine volume per subject was 15 mL (range: 5-48 mL). The highest peak serum lidocaine level detected at any time point (blood draw) for any subject was 0.3 microg/mL. Mean serum lidocaine level for all 6 time points was less than 0.1 microg/mL and was thus not detected. Detectable lidocaine levels were found to be associated with higher mean (P = .028) and median (P = .008) total lidocaine doses. Because no toxic levels were detected, it was not possible to measure sustained high lidocaine levels. LIMITATIONS: Limitations of this study include the lack of use of very concentrated (eg, 2% vs 1%) lidocaine solution. CONCLUSIONS: Lidocaine use during Mohs micrographic surgery does not appear to result in serum lidocaine levels approaching toxic levels even when relatively high total lidocaine doses are used. There is an association between higher total lidocaine dose and perioperative peak serum lidocaine level.